A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00700102 |
Recruitment Status :
Completed
First Posted : June 18, 2008
Results First Posted : July 30, 2015
Last Update Posted : July 30, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colorectal Cancer | Drug: Chemotherapy Drug: Bevacizumab | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 820 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination |
Study Start Date : | February 2006 |
Actual Primary Completion Date : | May 2013 |
Actual Study Completion Date : | May 2013 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Chemotherapy
Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
|
Drug: Chemotherapy
As prescribed |
Experimental: Chemotherapy + Bevacizumab
Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
|
Drug: Chemotherapy
As prescribed Drug: Bevacizumab Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.
Other Name: Avastin |
- Overall Survival: Time From Randomization to Death From Any Cause [ Time Frame: within 6.5 years ]
- Overall Survival: Months From Time of First Line Therapy [ Time Frame: within approximately 9.6 years ]
- Participants With Progression Free Survival Event [ Time Frame: within 6.5 years ]
- Progression Free Survival: Time to Event [ Time Frame: within 6.5 years ]
- Response Rate: Percentage of Participants With Best Overall Response, Defined as Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST Criteria [ Time Frame: within 6.5 years ]
- Response Rate: Participants With Response Status Based on RECIST Criteria [ Time Frame: within 6.5 years ]Response Evaluation Criteria In Solid Tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult patients, >=18 years of age
- Metastatic colorectal cancer and disease progression
- Previously treated with first-line chemotherapy plus Avastin
- Eastern Cooperative Oncology Group (ECOG) performance status <=2.
Exclusion Criteria:
- Diagnosis of progression of disease more than 3 months after last Avastin administration
- First-line patients with progression-free survival in first-line of <3 months
- Patients receiving less than 3 consecutive months of Avastin in first-line therapy
- Past or current history (within the last 2 years prior to treatment start) of other malignancies, except for curatively treated basal and squamous cell cancer of the skin or in situ cancer of the cervix
- Clinically significant cardiovascular disease within 6 months prior to start of study treatment
- Known central nervous system (CNS) disease, except for treated CNS metastases as defined by protocol
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00700102
Study Director: | Clinical Trials | Hoffmann-La Roche |
Responsible Party: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT00700102 |
Other Study ID Numbers: |
ML18147 2006-004634-32 ( EudraCT Number ) |
First Posted: | June 18, 2008 Key Record Dates |
Results First Posted: | July 30, 2015 |
Last Update Posted: | July 30, 2015 |
Last Verified: | July 2015 |
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases |
Rectal Diseases Bevacizumab Antineoplastic Agents, Immunological Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors |